Short answer · Medically reviewed summary · Last updated: 2026-05-08
Dermatofibrosarcoma protuberans (DFSP) was first formally described in the early 20th century, evolving from a clinical curiosity to a well-defined soft tissue sarcoma characterized by its distinct genetic signature. Today, our understanding of Dermatofibrosarcoma protuberans (DFSP) has shifted from surgical management alone to targeted molecular therapies, significantly improving outcomes for patients within our community of 172 members at DiseaseMaps.org. When was Dermatofibrosarcoma protuberans (DFSP) first identified? While various skin lesions were documented throughout the 1800s, the specific entity we now call Dermatofibrosarcoma protuberans (DFSP) was first characterized by Darier and Ferrand in 1924 as "progressing recurring dermatofibroma." In 1930, Hoffmann officially coined the term "dermatofibrosarcoma protuberans." Early clinicians often misidentified the tumor as a benign keloid or a simple dermatofibroma, leading to high rates of recurrence due to inadequate surgical margins. How has the understanding of DFSP evolved? The history of Dermatofibrosarcoma protuberans (DFSP) is marked by the discovery of the t(17;22)(q22;q13) chromosomal translocation in the 1990s.
1 people with Dermatofibrosarcoma Protuberans (DFSP) have shared their first-person experience on this question at DiseaseMaps.
What is the history of Dermatofibrosarcoma Protuberans (DFSP)?
History of Dermatofibrosarcoma Protuberans (DFSP): when and how it was discovered, and the milestones in research since, medically reviewed.
Dermatofibrosarcoma protuberans (DFSP) was first formally described in the early 20th century, evolving from a clinical curiosity to a well-defined soft tissue sarcoma characterized by its distinct genetic signature. Today, our understanding of Dermatofibrosarcoma protuberans (DFSP) has shifted from surgical management alone to targeted molecular therapies, significantly improving outcomes for patients within our community of 172 members at DiseaseMaps.org.
When was Dermatofibrosarcoma protuberans (DFSP) first identified?
While various skin lesions were documented throughout the 1800s, the specific entity we now call Dermatofibrosarcoma protuberans (DFSP) was first characterized by Darier and Ferrand in 1924 as "progressing recurring dermatofibroma." In 1930, Hoffmann officially coined the term "dermatofibrosarcoma protuberans." Early clinicians often misidentified the tumor as a benign keloid or a simple dermatofibroma, leading to high rates of recurrence due to inadequate surgical margins.
How has the understanding of DFSP evolved?
The history of Dermatofibrosarcoma protuberans (DFSP) is marked by the discovery of the t(17;22)(q22;q13) chromosomal translocation in the 1990s. This genetic breakthrough revealed that the condition is driven by the fusion of the COL1A1 and PDGFB genes. This discovery transformed Dermatofibrosarcoma protuberans (DFSP) from a "mysterious skin growth" into a molecularly defined malignancy.
What are the major milestones in treatment?
Treatment for Dermatofibrosarcoma protuberans (DFSP) has seen three major historical shifts:
- Wide Local Excision: Historically the primary treatment, often requiring wide margins to prevent the high local recurrence rates associated with the tumor's tentacle-like growth.
- Mohs Micrographic Surgery (MMS): Adopted to better map tumor margins, ensuring higher rates of complete resection.
- Targeted Therapy: The approval of imatinib mesylate in the early 2000s revolutionized care for advanced or unresectable Dermatofibrosarcoma protuberans (DFSP) by specifically blocking the signaling pathways activated by the PDGFB fusion.
Next steps
- Consult with a specialized sarcoma oncologist or a dermatologist experienced in Mohs surgery.
- Connect with the 172 members at DiseaseMaps.org to share experiences and coping strategies.
- Request genetic testing to confirm the COL1A1-PDGFB fusion if diagnosis remains uncertain.
Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Dermatofibrosarcoma protuberans.
- Orphanet: Dermatofibrosarcoma protuberans (ORPHA:231).
- OMIM (Online Mendelian Inheritance in Man): Entry #607901.
- National Cancer Institute (NCI): Soft Tissue Sarcoma Treatment guidelines.
Posted Sep 12, 2017 by Deana 2000
